A 74-year-old male with a cT1cN0M0, Gleason 4 + 3, and a pre-treatment prostate specific antigen (PSA) of 3.9 ng/mL, NCCN unfavorable intermediate-risk adenocarcinoma of the prostate was prescribed combination therapy with prostate HDR brachytherapy to 15 Gy in 1 fraction followed by pelvic nodes external beam RT to 46 Gy in 23 fractions with neoadjuvant, concurrent and adjuvant ADT for 4 months. Here, KLK3 is linked to prostate adenocarcinoma.